Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Wanbury Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹237.27Fairly Valued by 8.03%vs CMP ₹258.00

P/E (21.0) × ROE (76.5%) × BV (₹18.10) × DY (2.00%)

₹120.39Overvalued by 53.34%vs CMP ₹258.00
MoS: -114.3% (Negative)Confidence: 65/100 (Moderate)Models: All 8: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹208.6025%Over (-19.1%)
Graham NumberEarnings₹73.0415%Over (-71.7%)
Earnings PowerEarnings₹16.3412%Over (-93.7%)
DCFCash Flow₹70.0915%Over (-72.8%)
Net Asset ValueAssets₹16.888%Over (-93.5%)
EV/EBITDAEnterprise₹214.8110%Over (-16.7%)
Earnings YieldEarnings₹131.008%Over (-49.2%)
Revenue MultipleRevenue₹171.626%Over (-33.5%)
Consensus (8 models)₹120.39100%Overvalued
Key Drivers: Wide model spread (₹16–₹215) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -12.1%

*Investments are subject to market risks

Analyst Summary

Wanbury Ltd operates in the Pharmaceuticals segment, NSE: WANBURY | BSE: 524212, current market price is ₹258.00, market cap is 902 Cr.. At a glance, stock P/E is 21.0, ROE is 76.5 %, ROCE is 36.7 %, book value is 18.1, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹120.39, around 53.3% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹600 Cr versus the prior period change of 3.8%, while latest net profit is about ₹31 Cr with a prior-period change of -44.6%. The 52-week range shown on this page is 330/162, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisWanbury Ltd. is a Public Limited Listed company incorporated on 11/08/1988 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L51900MH1…

This summary is generated from the stock page data available for Wanbury Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

66
Wanbury Ltd scores 66/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health68/100 · Strong
ROCE 36.7% ExcellentROE 76.5% ExcellentD/E -0.56 Low debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 43.1% Stable
Earnings Quality65/100 · Strong
OPM expanding (6% → 13%) Improving
Quarterly Momentum60/100 · Moderate
Revenue (4Q): +12% YoY GrowingProfit (4Q): -19% YoY DecliningOPM: 15.0% (up 7.0% YoY) Margin expansion
Industry Rank85/100 · Strong
P/E 21.0 vs industry 60.0 Cheaper than peersROCE 36.7% vs industry 16.4% Above peersROE 76.5% vs industry 15.2% Above peers3Y sales CAGR: 5% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 26, 2026, 12:36 am

Market Cap 902 Cr.
Current Price 258
Intrinsic Value₹120.39
High / Low 330/162
Stock P/E21.0
Book Value 18.1
Dividend Yield0.00 %
ROCE36.7 %
ROE76.5 %
Face Value 10.0
PEG Ratio-1.74

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Wanbury Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Wanbury Ltd 902 Cr. 258 330/16221.0 18.10.00 %36.7 %76.5 % 10.0
Themis Medicare Ltd 888 Cr. 96.4 179/65.0 41.30.52 %10.4 %7.65 % 1.00
Fermenta Biotech Ltd 937 Cr. 318 399/25210.6 1330.79 %23.0 %24.9 % 5.00
Anuh Pharma Ltd 813 Cr. 81.1 115/66.719.4 32.61.85 %17.2 %13.4 % 5.00
Kopran Ltd 789 Cr. 164 213/10747.7 1041.83 %9.75 %7.64 % 10.0
Industry Average19,919.00 Cr1,121.4360.03201.540.36%16.41%15.21%6.10

All Competitor Stocks of Wanbury Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 117124126133146144146139131161133172163
Expenses 120118119119133127124121120141120142139
Operating Profit -36614131721181120143024
OPM % -3%5%5%11%9%12%15%13%8%12%10%17%15%
Other Income 210-31112612120
Interest 347868878101098
Depreciation 3333333333334
Profit before tax -7-1-315710341811914
Tax % -3%25%8%-11%6%-2%-0%1%0%2%5%-6%1%
Net Profit -7-1-315710341812013
EPS in Rs -2.21-0.27-1.000.311.432.253.1410.270.322.450.376.184.10

Last Updated: August 20, 2025, 1:15 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:08 am

MetricSep 2014n n 18mMar 2015n n 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 661250420432370391367392511485578600630
Expenses 637228387414438375344374475459503520542
Operating Profit 25213319-681623183626758088
OPM % 4%9%8%4%-18%4%6%5%7%5%13%13%14%
Other Income -78609076984277-324-05
Interest 48193236314033232121293737
Depreciation 235910101010101112131314
Profit before tax -1254-762-32-2565-1281-10563042
Tax % 2%28%0%1%-1%-1%0%2%-0%1%1%-3%
Net Profit -1283-762-32-2564-1381-10563143
EPS in Rs -63.951.60-3.5826.71-13.49-10.4825.79-5.0424.94-3.1817.099.3213.10
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)985.71%-151.61%21.88%356.00%-120.31%723.08%-112.35%660.00%-44.64%
Change in YoY Net Profit Growth (%)0.00%-1137.33%173.49%334.12%-476.31%843.39%-835.42%772.35%-704.64%

Wanbury Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:10%
3 Years:5%
TTM:12%
Compounded Profit Growth
10 Years:25%
5 Years:30%
3 Years:75%
TTM:60%
Stock Price CAGR
10 Years:16%
5 Years:49%
3 Years:61%
1 Year:15%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:70%

Last Updated: September 5, 2025, 1:55 pm

Balance Sheet

Last Updated: October 10, 2025, 3:15 pm

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 202020232424252533333333
Reserves -212-214-209-176-208-233-168-181-56-66-526
Borrowings 38938136230025026019019210095116179
Other Liabilities 209209215265207236232253276241199176
Total Liabilities 406396388412273286279289353304343414
Fixed Assets 174164180186178172164167167167167201
CWIP 1319141010914112235
Investments 000000000000
Other Assets 21921319321684105101111183135173208
Total Assets 406396388412273286279289353304343414

Reserves and Borrowings Chart

Cash Flow

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 68404343323044174120526
Cash from Investing Activity + -6-5-20-13-1-36481-9-17-51
Cash from Financing Activity + -71-30-28-27-33-27-108-17-29-321426
Net Cash Flow -95-53-2-0-0713-2121
Free Cash Flow 5635222930253612427-9-23
CFO/OP 278%188%129%234%-49%188%188%97%113%76%6%33%

Free Cash Flow

MonthMar 2015n n 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2014n n 18m
Free Cash Flow21.00-329.00-281.00-318.00-244.00-167.00-174.00-64.00-69.00-41.00-99.0025.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthSep 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 5714465712941503245525670
Inventory Days 4210369632736254160264347
Days Payable 113301172260174209253221218179196172
Cash Conversion Cycle -14-55-38-125-118-131-177-148-113-101-96-55
Working Capital Days -44-140-123-185-277-254-236-251-153-152-374
ROCE %4%12%57%-1%26%31%27%46%21%61%37%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 39.84%39.84%39.80%39.79%39.79%39.79%39.77%39.76%39.76%39.63%43.09%43.08%
FIIs 0.00%0.00%0.00%0.00%0.18%0.22%1.02%0.84%1.55%1.59%0.82%0.72%
Public 60.16%60.16%60.19%60.20%60.02%59.97%59.21%59.40%58.68%58.79%56.08%56.21%
No. of Shareholders 11,91111,74111,63411,61613,08714,40017,19917,99917,88917,89417,71717,261

Shareholding Pattern Chart

No. of Shareholders

Wanbury Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 9.3217.10-3.1825.29-5.04
Diluted EPS (Rs.) 8.9816.89-3.1825.21-5.04
Cash EPS (Rs.) 13.3821.070.6028.45-1.14
Book Value[Excl.RevalReserv]/Share (Rs.) 18.098.53-10.03-7.17-62.46
Book Value[Incl.RevalReserv]/Share (Rs.) 18.098.53-10.03-7.17-62.46
Revenue From Operations / Share (Rs.) 182.94175.79152.77156.49156.91
PBDIT / Share (Rs.) 24.3522.297.3611.278.16
PBIT / Share (Rs.) 20.2918.313.587.774.26
PBT / Share (Rs.) 9.0217.20-3.1524.84-4.96
Net Profit / Share (Rs.) 9.3217.09-3.1824.94-5.04
NP After MI And SOA / Share (Rs.) 9.3217.09-3.1824.94-5.04
PBDIT Margin (%) 13.3112.674.827.205.20
PBIT Margin (%) 11.0910.412.344.962.71
PBT Margin (%) 4.929.78-2.0515.87-3.16
Net Profit Margin (%) 5.099.72-2.0815.93-3.21
NP After MI And SOA Margin (%) 5.099.72-2.0815.93-3.21
Return on Networth / Equity (%) 51.50200.260.00-347.880.00
Return on Capital Employeed (%) 27.7846.34-70.89-351.22-16.12
Return On Assets (%) 7.3716.29-3.4223.10-4.35
Long Term Debt / Equity (X) 2.702.930.000.00-0.46
Total Debt / Equity (X) 2.923.94-1.95-2.86-0.56
Asset Turnover Ratio (%) 1.581.781.521.601.39
Current Ratio (X) 1.110.740.380.480.28
Quick Ratio (X) 0.890.570.310.340.21
Inventory Turnover Ratio (X) 16.279.977.188.1811.52
Interest Coverage Ratio (X) 2.162.501.131.790.88
Interest Coverage Ratio (Post Tax) (X) 1.832.040.541.250.45
Enterprise Value (Cr.) 929.36581.65182.26319.37284.21
EV / Net Operating Revenue (X) 1.551.010.360.620.72
EV / EBITDA (X) 11.647.977.578.6713.92
MarketCap / Net Operating Revenue (X) 1.280.820.240.540.52
Price / BV (X) 12.9717.09-3.72-11.86-1.33
Price / Net Operating Revenue (X) 1.280.820.240.540.52
EarningsYield 0.030.11-0.080.29-0.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Wanbury Ltd. is a Public Limited Listed company incorporated on 11/08/1988 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L51900MH1988PLC048455 and registration number is 048455. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 599.51 Cr. and Equity Capital is Rs. 32.77 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBSEL Tech Park, B-Wing, 10th Floor, Sector 30-A, New Mumbai Maharashtra 400703Contact not found
Management
NamePosition Held
Mr. K ChandranWhole Time Director
Mr. Mohan Kumar RayanaWhole Time Director
Ms. Anupama VaidyaInd. Non-Executive Woman Director
Mr. Mridul Sumanlal MehtaInd. Non-Executive Director
Mr. P V Sankar DassInd. Non-Executive Director
Mr. Manojkumar K GursahaniInd. Non-Executive Director

FAQ

What is the intrinsic value of Wanbury Ltd and is it undervalued?

As of 04 May 2026, Wanbury Ltd's intrinsic value is ₹120.39, which is 53.34% lower than the current market price of ₹258.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (76.5 %), book value (₹18.1), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Wanbury Ltd?

Wanbury Ltd is trading at ₹258.00 as of 04 May 2026, with a FY2026-2027 high of ₹330 and low of ₹162. The stock is currently in the middle of its 52-week range. Market cap stands at ₹902 Cr..

How does Wanbury Ltd's P/E ratio compare to its industry?

Wanbury Ltd has a P/E ratio of 21.0, which is below the industry average of 60.03. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Wanbury Ltd financially healthy?

Key indicators for Wanbury Ltd: ROCE of 36.7 % indicates efficient capital utilization; ROE of 76.5 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Wanbury Ltd profitable and how is the profit trend?

Wanbury Ltd reported a net profit of ₹31 Cr in Mar 2025 on revenue of ₹600 Cr. Compared to ₹81 Cr in Mar 2022, the net profit shows a declining trend.

Does Wanbury Ltd pay dividends?

Wanbury Ltd has a dividend yield of 0.00 % at the current price of ₹258.00. The company is currently not paying meaningful dividends.

Last Updated: April 26, 2026, 12:36 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524212 | NSE: WANBURY
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Wanbury Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports